title: Some behavioral effects of AMPA/kainate receptor agonist and antagonists.
abstract: The effects of an agonist (S-AMPA, i.c.v.), as well as competitive (CNQX, NBQX, DNQX, i.p.), and noncompetitive antagonists (GYKI 52466, i.p.) at the AMPA/kainate receptors were examined in the open field and the Vogel tests of anxiety. It was found that both kinds of antagonists inhibited rat exploratory behavior in a dose-dependent manner, at the dose range exhibiting a clear-cut tendency to decrease rat locomotor activity. They appeared inactive in the Vogel test over an examined dose-range. S-AMPA, whereas not changing in a significant way rat behavior in the open field, significantly enhanced the suppressive influence of a shock on drinking in the Vogel test. The drug administered at the dose of 2 micrograms/5 microliters, i.c.v., revealed also a tendency to decrease the motor activity followed by prodromal symptoms of epileptic-like activity in some subjects. It is concluded that AMPA/kainate receptors probably are not directly involved in the control of rat emotional behavior. Thus, their primary role as putative neuroprotective and anticonvulsant agents is indirectly confirmed.
authors.affiliation: Department of Experimental and Clinical Pharmacology, Medical Academy, Warsaw, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Członkowska
authors.forename: M
authors.initials: M
authors.lastname: Siemiatkowski
authors.forename: A
authors.initials: A
authors.lastname: Płaźnik
mesh_terms: D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000818:Animals; D014151:Anti-Anxiety Agents; D001007:Anxiety / Q000503:physiopathology; D001522:Behavior, Animal / Q000187:drug effects*; D001569:Benzodiazepines / Q000494:pharmacology; D003220:Conflict, Psychological; D004327:Drinking Behavior / Q000187:drug effects; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D005106:Exploratory Behavior / Q000187:drug effects; D008297:Male; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018091:Receptors, AMPA / Q000819:agonists / Q000037:antagonists & inhibitors / Q000187:drug effects*; D018092:Kainic Acid Receptors / Q000819:agonists / Q000037:antagonists & inhibitors / Q000187:drug effects*; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000494:pharmacology
chemical_list: D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D011810:Quinoxalines; D018091:Receptors, AMPA; D018092:Kainic Acid Receptors; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; C061950:GYKI 52466; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; C056723:FG 9041